Liposomal and liposome-based formulations of pentacyclic triterpenoids in cancer nanomedicine: A critical appraisal of preclinical progress and future perspectives

Mahsa Babaei, Mehran Miroliaei

Open source

DOI
10.1016/j.biopha.2026.120011
Published
2026-11
Container
Biomedicine & Pharmacotherapy
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.biopha.2026.120011,
  title = {Liposomal and liposome-based formulations of pentacyclic triterpenoids in cancer nanomedicine: A critical appraisal of preclinical progress and future perspectives},
  author = {Mahsa Babaei and Mehran Miroliaei},
  year = {2026},
  journal = {Biomedicine \& Pharmacotherapy},
  doi = {10.1016/j.biopha.2026.120011},
  url = {https://doi.org/10.1016/j.biopha.2026.120011}
}

RIS

TY  - JOUR
TI  - Liposomal and liposome-based formulations of pentacyclic triterpenoids in cancer nanomedicine: A critical appraisal of preclinical progress and future perspectives
AU  - Mahsa Babaei
AU  - Mehran Miroliaei
PY  - 2026
JO  - Biomedicine & Pharmacotherapy
DO  - 10.1016/j.biopha.2026.120011
UR  - https://doi.org/10.1016/j.biopha.2026.120011
ER  - 

APA

Babaei, M., & Miroliaei, M. (2026). Liposomal and liposome-based formulations of pentacyclic triterpenoids in cancer nanomedicine: A critical appraisal of preclinical progress and future perspectives. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2026.120011

Source records